Kingdon Capital Management L.L.C. Purchases 87,650 Shares of Globus Medical, Inc. $GMED

Kingdon Capital Management L.L.C. increased its stake in Globus Medical, Inc. (NYSE:GMED) by 51.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 257,650 shares of the medical device company’s stock after purchasing an additional 87,650 shares during the quarter. Globus Medical makes up approximately 1.8% of Kingdon Capital Management L.L.C.’s portfolio, making the stock its 14th biggest holding. Kingdon Capital Management L.L.C.’s holdings in Globus Medical were worth $14,756,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC lifted its holdings in shares of Globus Medical by 74.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after acquiring an additional 197 shares during the last quarter. Advisors Asset Management Inc. bought a new stake in Globus Medical during the second quarter worth about $28,000. First Horizon Corp bought a new stake in Globus Medical during the third quarter worth about $31,000. Parallel Advisors LLC boosted its holdings in shares of Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after purchasing an additional 173 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Globus Medical in the 3rd quarter worth about $36,000. Hedge funds and other institutional investors own 95.16% of the company’s stock.

Globus Medical Trading Up 0.4%

Globus Medical stock opened at $84.81 on Monday. The firm has a market cap of $11.47 billion, a price-to-earnings ratio of 21.52, a PEG ratio of 1.99 and a beta of 1.05. The stock has a fifty day simple moving average of $90.71 and a two-hundred day simple moving average of $78.49. Globus Medical, Inc. has a 12 month low of $51.79 and a 12 month high of $101.40.

Globus Medical (NYSE:GMED) last announced its quarterly earnings results on Tuesday, February 24th. The medical device company reported $1.28 EPS for the quarter, topping analysts’ consensus estimates of $1.06 by $0.22. Globus Medical had a net margin of 18.30% and a return on equity of 12.57%. The firm had revenue of $826.42 million during the quarter, compared to analyst estimates of $803.29 million. During the same period in the previous year, the business posted $0.84 earnings per share. The business’s revenue for the quarter was up 25.7% on a year-over-year basis. On average, equities research analysts forecast that Globus Medical, Inc. will post 3.44 EPS for the current fiscal year.

Trending Headlines about Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Zacks Research sharply raised EPS forecasts across multiple quarters and years and maintained a “Strong‑Buy” rating — the firm bumped Q1, Q2 and Q3 2027 estimates and raised FY2026 and FY2027 outlooks (FY2027 to $4.66). Improved analyst earnings trajectories support higher forward valuations and raise the bar for future guidance. Zacks Research Raises Earnings Estimates for Globus Medical
• Positive Sentiment: Brokerage consensus sits at an average “Moderate Buy” rating — this aggregate analyst view suggests continued institutional support and can attract momentum buying as earnings estimates move higher. Globus Medical Given Average Rating of “Moderate Buy” by Brokerages
• Neutral Sentiment: Technical/valuation context is mixed — GMED is trading above its 200‑day moving average (longer‑term support) but below its 50‑day average (shorter‑term momentum). The stock still trades at a mid‑teens to low‑20s P/E on forward estimates, so further upside may depend on continued estimate upgrades or stronger organic revenue/ margin beats. MarketBeat GMED Page

Insider Buying and Selling

In related news, CFO Kyle Kline sold 3,594 shares of the stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $101.10, for a total transaction of $363,353.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kelly Huller sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total value of $1,890,000.00. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 35,594 shares of company stock worth $3,332,253. 18.54% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have commented on GMED shares. Needham & Company LLC lifted their price target on shares of Globus Medical from $112.00 to $114.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Wells Fargo & Company increased their target price on shares of Globus Medical from $98.00 to $104.00 and gave the company an “overweight” rating in a report on Thursday, February 26th. Canaccord Genuity Group lifted their target price on shares of Globus Medical from $105.00 to $112.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. Piper Sandler reissued an “overweight” rating and issued a $115.00 target price (up from $90.00) on shares of Globus Medical in a research note on Thursday, January 8th. Finally, Barclays increased their target price on Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $104.36.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.